Manchester Capital Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $60.5K | Buy |
1,096
+405
| +59% | +$21.9K | 0.01% | 457 |
|
|
2025
Q4 | $33.9K | Sell |
691
-44
| -6% | -$2.05K | ﹤0.01% | 559 |
|
|
2025
Q3 | $31.7K | Buy |
735
+275
| +60% | +$10.7K | ﹤0.01% | 652 |
|
|
2025
Q2 | $17.7K | Sell |
460
-107
| -19% | -$4.09K | ﹤0.01% | 737 |
|
|
2025
Q1 | $22K | Buy |
567
+70
| +14% | +$2.56K | ﹤0.01% | 695 |
|
|
2024
Q4 | $16.8K | Sell |
497
-370
| -43% | -$13.3K | ﹤0.01% | 734 |
|
|
2024
Q3 | $35.4K | Sell |
867
-9
| -1% | -$368 | ﹤0.01% | 599 |
|
|
2024
Q2 | $33.7K | Buy |
876
+495
| +130% | +$20.8K | ﹤0.01% | 569 |
|
|
2024
Q1 | $16.3K | Hold |
381
| – | – | ﹤0.01% | 579 |
|
|
2023
Q4 | $14.1K | Hold |
381
| – | – | ﹤0.01% | 575 |
|
|
2023
Q3 | $13.8K | Sell |
381
-18
| -5% | -$639 | ﹤0.01% | 565 |
|
|
2023
Q2 | $14.2K | Buy |
399
+154
| +63% | +$5.52K | ﹤0.01% | 529 |
|
|
2023
Q1 | $8.72K | Buy |
245
+64
| +35% | +$2.24K | ﹤0.01% | 562 |
|
|
2022
Q4 | $6.36K | Sell |
181
-451
| -71% | -$15K | ﹤0.01% | 509 |
|
|
2022
Q3 | $19K | Sell |
632
-55
| -8% | -$2.08K | ﹤0.01% | 409 |
|
|
2022
Q2 | $37K | Buy |
687
+228
| +50% | +$12.6K | 0.01% | 380 |
|
|
2022
Q1 | $25K | Hold |
459
| – | – | ﹤0.01% | 441 |
|
|
2021
Q4 | $25K | Sell |
459
-62
| -12% | -$3.23K | ﹤0.01% | 462 |
|
|
2021
Q3 | $25K | Buy |
521
+216
| +71% | +$10.8K | ﹤0.01% | 487 |
|
|
2021
Q2 | $15K | Buy |
305
+225
| +281% | +$10.8K | ﹤0.01% | 462 |
|
|
2021
Q1 | $4K | Hold |
80
| – | – | ﹤0.01% | 547 |
|
|
2020
Q4 | $4K | Sell |
80
-800
| -91% | -$36.7K | ﹤0.01% | 546 |
|
|
2020
Q3 | $41K | Hold |
880
| – | – | 0.01% | 349 |
|
|
2020
Q2 | $45K | Hold |
880
| – | – | 0.01% | 376 |
|
|
2020
Q1 | $42K | Hold |
880
| – | – | 0.01% | 372 |
|
|
2019
Q4 | $52K | Hold |
880
| – | – | 0.01% | 365 |
|
|
2019
Q3 | $47K | Hold |
880
| – | – | 0.01% | 369 |
|
|
2019
Q2 | $44K | Hold |
880
| – | – | 0.01% | 391 |
|
|
2019
Q1 | $46K | Hold |
880
| – | – | 0.01% | 417 |
|
|
2018
Q4 | $44K | Hold |
880
| – | – | 0.01% | 362 |
|
|
2018
Q3 | $44K | Hold |
880
| – | – | 0.01% | 364 |
|
|
2018
Q2 | $44K | Hold |
880
| – | – | 0.01% | 371 |
|
|
2018
Q1 | $43K | Buy |
880
+800
| +1,000% | +$37.3K | 0.01% | 369 |
|
|
2017
Q4 | $4K | Sell |
80
-800
| -91% | -$37K | ﹤0.01% | 463 |
|
|
2017
Q3 | $45K | Buy |
+880
| New | +$44.6K | 0.01% | 347 |
|
|
2016
Q4 | – | Sell |
-43
| Closed | -$2K | – | 503 |
|
|
2016
Q3 | $2K | Hold |
43
| – | – | ﹤0.01% | 500 |
|
|
2016
Q2 | $2K | Hold |
43
| – | – | ﹤0.01% | 517 |
|
|
2016
Q1 | $2K | Sell |
43
-2,891
| -99% | -$144K | ﹤0.01% | 575 |
|
|
2015
Q4 | $148K | Buy |
+2,934
| New | +$150K | 0.02% | 252 |
|
|
2015
Q1 | – | Sell |
-2,509
| Closed | -$134K | – | 677 |
|
|
2014
Q4 | $134K | Sell |
2,509
-490
| -16% | -$27.4K | 0.02% | 469 |
|
|
2014
Q3 | $172K | Sell |
2,999
-728
| -20% | -$44.6K | 0.02% | 388 |
|
|
2014
Q2 | $249K | Buy |
+3,727
| New | +$252K | 0.03% | 309 |
|
Other funds holding GSK
JEST
Manchester Capital Management's GSK Position: Q1 2026 in Review
Manchester Capital Management increased its GSK (GSK) stake by 59% in Q1 2026, buying an estimated $21.9K and bringing the position to 1,096 shares worth $60.5K. The position accounts for 0.01% of the portfolio, ranked #457.
Manchester Capital Management first reported a position in GSK in Q2 2014 and has held it in 42 quarters since. The position peaked at $249K in Q2 2014. 1,033 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Manchester Capital Management held 1,096 shares of GSK worth $60.5K as of Q1 2026.
- Manchester Capital Management bought 405 GSK shares in Q1 2026, an estimated $21.9K.
- GSK made up 0.01% of Manchester Capital Management's portfolio in Q1 2026, its #457 holding.
- Manchester Capital Management first reported a position in GSK in Q2 2014 and has held it in 42 quarters since.
- Manchester Capital Management's GSK position peaked at $249K in Q2 2014.
- 1,033 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.